Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer
FRIDAY, April 22, 2022 -- The addition of tislelizumab to chemotherapy improves progression-free survival (PFS) in recurrent/metastatic nasopharyngeal cancer (RM NPC), according to a study presented April 18 as part of the American Society for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 22, 2022 Category: Pharmaceuticals Source Type: news
PD-1 Inhibition Shows 'Clear' Benefit in Nasopharyngeal Carcinoma
(MedPage Today) -- Adding the PD-1 inhibitor tislelizumab to chemotherapy led to a progression-free survival (PFS) improvement for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to updated results from a phase III... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 20, 2022 Category: Hematology Source Type: news
Cancer: The 'kissing disease' that may lead to nasopharyngeal cancer – symptoms
CANCER detection - and treatment - in the earliest stages can greatly affect a person's survival rate. Would you be aware of the first symptom of nasopharyngeal cancer, which begins at the upper part of the throat? (Source: Daily Express - Health)
Source: Daily Express - Health - March 14, 2022 Category: Consumer Health News Source Type: news
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma
(MedPage Today) -- Use of elective ipsilateral upper-neck irradiation (UNI) in patients with nasopharyngeal carcinoma provided similar regional control as whole-neck irradiation (WNI), and resulted in less late toxicity, according to Chinese researchers... (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - March 2, 2022 Category: Radiology Source Type: news
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Media News - December 3, 2021 Category: Pharmaceuticals Source Type: news
Roche has rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Investor Update - December 3, 2021 Category: Pharmaceuticals Source Type: news
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 1, 2021 Category: Drugs & Pharmacology Source Type: news
Sensitive and specific detecting biomarker of radiation-resistant nasopharyngeal carcinoma
(World Scientific) In our study, we constructed a detecting platform based on TpTta-COF nanosheets and fluorescent probe. The TpTta-COF nanosheets can adsorb single-stranded DNA (ss-DNA) probes and quench the fluorescence of ss-DNA. The method enables to capture miR-205 sensitively in aqueous solution with a detection limit of 4.78 nM in the range 0-500 nM and R2 = 0.989, and the method offers great specificity in that it can distinguish the target miRNA from mismatch non-target miRNAs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news
New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer
Improved survival in a phase 3 trial where the new drug was added onto chemotherapy could move immunotherapy to the first line, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lobaplatin'Promising' in Nasopharyngeal Cancer Lobaplatin'Promising' in Nasopharyngeal Cancer
Lobaplatin-based induction plus chemoradiation was as effective as, and safer than, a cisplatin-based regimen in a phase 3 trial in China.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 4, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Creation of 3D organoid models to fine-tune radiation dose for nasopharyngeal cancer
(Agency for Science, Technology and Research (A*STAR), Singapore) A*STAR's Institute of Bioengineering and Nanotechnology (IBN) has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd (SIAMH) to establish the first of its kind in-vitro patient-derived 3D organoid models of Nasopharyngeal Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news
Cancer symptoms: The first warning sign of nasopharyngeal cancer - a painless swelling
CANCER at the back of the nose, down to the throat - a type of head and neck disease - is called nasopharyngeal cancer. What are the symptoms of this deadly condition? And what are the risk factors? (Source: Daily Express - Health)
Source: Daily Express - Health - March 22, 2021 Category: Consumer Health News Source Type: news
ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma ASCO, CSCO Outline'Best Practices' for Nasopharyngeal Carcinoma
New evidence-based recommendations provide guidance on when to give radiotherapy and chemotherapy to patients with nasopharyngeal carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
What Is Nasopharyngeal Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 21, 2021 Category: General Medicine Source Type: news
